AstraZeneca stock holds steady as Q2 2026 earnings beat supports outlook
Published on 08/13/2026 at 15:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca Plc (ISIN US6549022043) stock is trading in the mid-$150s after the latest quarterly report showed that earnings per share and revenue for the second quarter of 2026 came in ahead of expectations, reinforcing the company’s profit growth story as of August 13, 2026.
Per a detailed earnings overview dated August 13, 2026, AstraZeneca reported quarterly EPS of $2.63 in its most recent results, exceeding consensus estimates of $2.50 and signaling continued operational leverage in its portfolio.
The same overview indicates that second-quarter 2026 revenue reached $15.38 billion, representing a 6.4 percent year-over-year increase, even though this figure was slightly below the $15.44 billion analysts had anticipated for the period.
Q2 2026 earnings beat and revenue growth
An earnings recap published on August 13, 2026 highlights that AstraZeneca’s latest quarterly EPS of $2.63 topped the average analyst estimate of $2.50 by $0.13, underscoring that the company is converting its expanding product base into faster profit growth.
In the same second-quarter 2026 report, revenue of $15.38 billion grew 6.4 percent compared with the prior-year quarter, when the company delivered $2.17 in EPS, showing that AstraZeneca is achieving both top-line expansion and improved per-share earnings off a higher base.
The earnings coverage also points out that AstraZeneca generated a return on equity of 31.45 percent and a net margin of 17.02 percent in the latest reported period, metrics that illustrate a strong balance between investment in pipeline and shareholder returns in fiscal 2026.
Fiscal 2025 context and current consensus
AstraZeneca’s longer-term trajectory has been supported by fiscal 2025 results, where revenue was reported at $58.74 billion compared with $54.07 billion in the previous fiscal year, a historical increase of approximately 8.7 percent that set a higher starting point for 2026 growth.
For the same fiscal 2025 period, the company posted $10.22 billion in net income and $14.23 billion in operating income, historical figures that show how AstraZeneca scaled earnings when multiple late-stage therapies moved closer to commercial maturity.
Current-year projections referenced in the August 13, 2026 earnings summary indicate that equity analysts expect AstraZeneca to deliver 10.21 in earnings per share for the full current year, suggesting that the Q2 2026 EPS beat could translate into continued double-digit annual EPS on a reported basis.
Analyst stance and valuation backdrop
According to a consensus snapshot within the same August 13, 2026 coverage, AstraZeneca carries a “Moderate Buy” rating profile supported by 12 Buy, two Hold, and one Sell recommendation, signaling a broadly constructive stance even as the stock consolidates below the average target.
The consensus average price target currently stands at $211 per share, which compares to a reported cash-market price of $158.14 for AstraZeneca stock at the latest close on August 12, 2026, implying upside potential of more than 30 percent if the company executes on its pipeline and guidance.
While target-price dispersion reflects differing views on competitive dynamics in oncology and immunology, the underlying metrics of a 31.45 percent return on equity and a 17.02 percent net margin support the notion that AstraZeneca is well positioned to fund late-stage development and potential acquisitions without over-leveraging its balance sheet.
Read more
More on AstraZeneca stock
The official shareholder information page provides direct access to AstraZeneca’s H1 and Q2 2026 results reports, including detailed breakdowns of revenue by therapeutic area, margins, and cash flow that underpin the current earnings narrative.
Key product: oncology portfolio as growth driver
AstraZeneca’s growth story in recent years has been heavily driven by its oncology portfolio, which includes a range of targeted therapies and immuno-oncology agents addressing lung cancer, breast cancer, and hematologic malignancies, among other indications.
These oncology products contributed significantly to the historical revenue increase from $54.07 billion in fiscal 2024 to $58.74 billion in fiscal 2025, as indicated by the income statement backdrop, and remain central to the company’s strategy in 2026 as it seeks to sustain high-teens margins while investing in next-generation combinations.
For investors, the continued expansion of oncology indications, label extensions, and regional approvals forms a critical pillar of AstraZeneca’s capacity to maintain mid-single-digit revenue growth and double-digit EPS, complementing contributions from cardiovascular, renal, and metabolic franchises.
Latest share price and market context
As of the most recent regular-session close on August 12, 2026, AstraZeneca stock on the New York Stock Exchange finished at $158.10, reflecting a daily decline of 0.41 percent and positioning the shares below the $211 consensus target highlighted in the August 13, 2026 earnings recap.
Market data from the same quote snapshot show that AstraZeneca’s market capitalization currently stands at $490.43 billion, which places the company among the world’s largest biopharma groups and gives it significant flexibility to fund clinical programs and potential licensing deals while still returning capital to shareholders.
From a valuation standpoint, the indicated trailing price-to-earnings multiple of 23.58 times based on the latest available data suggests that the market is pricing AstraZeneca stock at a premium to some diversified pharmaceutical peers, reflecting confidence in its oncology pipeline and late-stage assets as of August 13, 2026.
Fact box
Company: AstraZeneca Plc
ISIN: US6549022043
Ticker: AZN
Exchange: New York Stock Exchange (primary listing of ADR)
Price (as of August 12, 2026, 4:00 p.m. ET): $158.10 USD
Market cap: $490.43 billion (as of August 12, 2026)
Sector / Industry: Health care / Pharmaceuticals and biotechnology
Index membership: S&P 500
